This is a rare type of growth that involves both smooth muscle and lymphatic vessels. It can sometimes cause fluid to build up in the chest or abdomen. It's generally considered benign, meaning it's not cancer.
Every report comes from a Lived member, sent anonymously.
Have you tried Sirolimus for Lymphangiomyoma?
A lymphangiomyoma, also called a lymphangioleiomyoma, is a soft, fluid-filled mass that forms when abnormal smooth muscle-like cells grow into lymphatic vessels and lymph nodes. The lymphatic system drains lymph, a clear fluid, from the tissues, and after meals it also carries chyle, a milky, fat-rich fluid absorbed from the gut. When these cells crowd and partly block the channels, fluid backs up and the vessels swell into a mass. Most lymphangiomyomas sit at the back of the abdomen or in the pelvis; some form in the chest. Most lymphangiomyomas occur in people with lymphangioleiomyomatosis (LAM), a rare disease that mainly affects women between puberty and menopause. In LAM, the same cells grow in the lungs and create many small cysts that can gradually make breathing harder. About one in six people with LAM has lymphangiomyomas. Many cause no symptoms, but larger ones can cause pain, bloating or leg swelling, and on a scan they can look like cancer, which is one reason recognizing them matters. Very rarely, a single lymphangiomyoma is found in someone with no lung disease. The name is easy to confuse with lymphangioma, which is a different lymphatic growth.
A lymphangiomyoma is a feature of LAM rather than something set off by an injury or infection. LAM is caused by changes in one of two genes, TSC1 or TSC2, that normally help keep cell growth in check. In sporadic LAM, the gene change arises during a person's lifetime and is not passed on to children. LAM can also occur as part of tuberous sclerosis complex (TSC), an inherited condition that causes noncancerous growths in many organs; roughly a quarter to a half of women with TSC develop LAM. The hormone estrogen appears to drive the disease. LAM mostly affects women before menopause, and pregnancy, estrogen-containing medicines such as some birth control, and fertility treatment have all been linked with its onset or worsening. Lymphangiomyomas themselves can grow during pregnancy and have been seen to change size with the menstrual cycle. They also swell after eating, because meals increase the flow of chyle through channels that are already partly blocked; this is why they tend to be larger later in the day. They are more common in people whose LAM lung disease is more advanced.
A lymphangiomyoma is usually found on a CT scan, MRI or ultrasound of the abdomen or pelvis, either while looking into symptoms or by chance. It typically appears as a well-defined mass filled with low-density fluid, sometimes alongside enlarged lymph nodes, fluid in the abdomen or chest, or a widened thoracic duct (the body's main lymph channel). Because a lymphangiomyoma can resemble lymphoma or another tumor, the key next step is a high-resolution CT scan of the chest to look for the thin-walled lung cysts of LAM. When those typical cysts are present together with lymphangiomyomas, LAM can be diagnosed without a biopsy. Other findings point the same way: kidney growths called angiomyolipomas, signs of TSC, or a raised blood level of VEGF-D (vascular endothelial growth factor D), a growth signal that tends to be higher when LAM involves the lymphatic system. Repeating an ultrasound after several hours of fasting can also help, since these masses get measurably smaller when a person has not eaten, which helps tell them apart from a tumor. Needle biopsy or surgery to sample a lymphangiomyoma is generally avoided when LAM explains it. Tissue sampling is kept for situations where the overall picture stays unclear.
A lymphangiomyoma that causes no symptoms does not need treatment of its own. It can be watched with periodic scans while LAM as a whole is managed. When a lymphangiomyoma causes pain, bloating or swelling, the main treatment is sirolimus, a daily pill from a group of medicines called mTOR inhibitors that helps control the abnormal growth of LAM cells. It is the only medicine approved by the US Food and Drug Administration (FDA) for LAM. In observational studies and case series, lymphangiomyomas shrank considerably or disappeared over about six months, sometimes starting within a few weeks, and sirolimus also helped stabilize lung function and reduce chyle collections around the lungs and abdomen. No randomized trial has tested it for lymphangiomyomas specifically, and symptoms may return if the medicine is stopped. Everolimus, a related mTOR inhibitor, is sometimes used instead. Sirolimus works partly by suppressing the immune system, so it raises the risk of infections. Common side effects include mouth sores, diarrhea, nausea, acne, leg swelling and higher cholesterol. Blood tests check the drug level and watch for side effects. Sirolimus can harm a developing baby, so pregnancy needs to be planned with the care team. In LAM, surgery to remove a lymphangiomyoma is generally avoided, since medicine can usually shrink it. A rare isolated lymphangiomyoma in someone without LAM is a different situation, and surgical removal has been used successfully in reported cases. Care for the lungs and any kidney growths is planned at the same time, ideally with a lung specialist experienced in LAM.
Lymphangiomyomas often change in size. Because they fill with chyle after meals, many people notice bloating, abdominal fullness or leg swelling that builds as the day goes on. For people whose masses cause symptoms, sirolimus often brings relief as the masses shrink over months. Treatment generally continues at least until the lesions resolve, and often longer to protect the lungs. The longer-term outlook depends mostly on the lung disease rather than the lymphangiomyomas. LAM varies widely: some people have few symptoms for many years, while others lose lung function more quickly. Outcomes have improved, and studies in the United States report transplant-free survival of more than 20 years. Lung function tends to decline more slowly after menopause. Follow-up usually means regular breathing tests and a CT or MRI of the abdomen every one to two years, or sooner if something changes. Pregnancy can enlarge lymphangiomyomas and worsen LAM, so it is worth discussing well before trying to conceive. Air travel can raise the risk of a collapsed lung in people with LAM lung cysts, so it makes sense to check with your doctor before flying.
Arrange an evaluation if a scan has found an unexplained fluid-filled mass in the abdomen, pelvis or chest, especially if you are a woman with shortness of breath, known lung cysts or TSC, so that LAM can be considered before any biopsy or surgery is planned. Contact your care team if abdominal pain, bloating, waist size or leg swelling increases, if breathlessness gradually worsens, or if you take sirolimus and develop a fever or other signs of infection or mouth sores that make eating difficult. Sudden sharp chest pain with trouble breathing can mean a collapsed lung, a common complication of LAM, and needs emergency care right away.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Lymphangiomyoma is like, what's helped you, or ask the community a question.